News

Overview: Merck's $10.8 Billion Acquisition of Prometheus Biosciences

Basic Transaction Details: Acquiring Company Merck & Co. (NYSE: MRK) Target Company Prometheus Biosciences, Inc. Per Share EV $200 in cash Total Equity Value Approximately $10.8 Billion Announcement Date 16th June 2023 Financial Advisory Centerview Partners, Goldman Sachs (Prometheus Biosciences) Morgan Stanley (Merck) Legal Advisory Latham & Watkins LLP

News

Overview: Pfizer Makes Strategic Leap with $43 Billion Seagen Acquisition

Basic Transaction Details: Acquiring Company Pfizer Inc. Target Company Seagen Inc. Per Share Equity Value $229, at a premium of 35% Transaction Size $43 Billion Announcement Date 13th March 2023 Financial Advisory Centerview Partners (Seagen) Guggenheim Securities (Pfizer) Legal Advisory Sullivan & Cromwell (Seagen) Wachtell, Lipton, Rosen & Katz (Pfizer)